What now? Responding to relapse in hepatitis C.
Parkinson
Erin
E
D000428:Alcohol Drinking / Q000009:adverse effects; D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D009722:Nurse Practitioners / Q000458:organization & administration*; D010353:Patient Education as Topic; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011320:Primary Health Care / Q000458:organization & administration*; D011994:Recombinant Proteins; D012008:Recurrence; D012017:Referral and Consultation; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D019562:Viral Load
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C050739:interferon alfacon-1; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a